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Abstract  
Background. This study aims to identify comorbidities through various sources and to assess their 
short-term impact on relative survival in a cohort of Heart Failure (HF) patients. 
Methods. Newly hospitalized HF patients were identified from hospital discharge abstracts (HDA) 
of Lombardy Region, Italy, from 2008 to 2010. Charlson comorbidities were assessed by just HDA 
and supplemented by drug prescriptions and disease-specific exemptions. A Cox model for one-
year relative survival from HF was fitted. 
Results. The cohort consisted of 51,061 HF patients (53% women; median age 80 years). After 
integrating information from all sources, the prevalence of diabetes, chronic pulmonary disease 
and renal disease raised up to 27.6%, 26.2% and 14.2%, respectively. 
Survival in the HF cohort was inferior to that in the reference population and decreased with 
increasing number of comorbidities. Notably, the overall performance of the relative survival 
models was similar regardless of which strategy was used to ascertain comorbidity. 
Conclusions. The effort required to implement a comprehensive search method for comorbidities 
is worth the potential benefit when the aim is to assess the comorbidity burden. On the contrary, a 
search method limited to HDA can reasonably be used to determine a comorbidity profile for 
mortality risk adjustment purposes.  
 
Keywords: comorbidity; Charlson index; claims data; drug prescriptions; hospital discharges; 
relative survival 
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1. Introduction 
Heart Failure (HF) is a major and growing public health issue that affects all Western countries. 
Around 1-2% of the population in European countries suffers from HF, with the prevalence rising to 
above 10% among people aged 70 years and over [1].  
HF is commonly accompanied by a broad range of comorbidities, with chronic kidney disease, 
anaemia and diabetes being the most prevalent, which further complicate the management of care, 
unfavourably affecting prognosis [2, 3].  
Research on the epidemiology of HF has relied on multiple data sources [4]. Of these, claims data 
have been increasingly used for health services utilization and outcome evaluation [5, 6].  
Among methods to measure burden of comorbidity and case-mix, the Charlson comorbidity index 
[7] has been extensively used in claims-based investigations [8]. Nevertheless, it is recognized that 
administrative claims data may underestimate comorbidity burden [9, 10]. 
Some studies [11, 12] have explored the predictive validity of comorbidity measures when using 
claims data versus other clinical data sources, but few studies [9] to date have evaluated whether 
comorbidity-adjusted survival estimates change depending on incorporation of claims data on 
comorbidity from sources other than inpatient claims.  
This study aims to identify comorbidities through the use of multiple administrative data sources on 
health care use and to assess their short-term impact on relative survival in a large Italian cohort of 
Heart Failure (HF) patients. 
 
2. Methods 
2.1 Study population 
The Italian National Health Service (NHS) provides universal health care coverage to all Italian 
citizens. Essential health services are provided free of charge or at a minimal charge. Some 
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particular circumstances such as disability, chronic diseases, status of inability, low income or >65 
years of age entitle patients to co-payment fee exemption. 
The reference population for this study consists of all beneficiaries of the NHS, resident in 
Lombardy Region, an industrialized Italian region with 10 million inhabitants. Among these, 
subjects firstly hospitalized with a diagnosis of HF from January 2008 to December 2010 
constitute the study population.  
Data are drawn from the Lombardy Health Information System, including Hospital Discharge 
Abstracts (HDA) database, Drugs Prescriptions Register (DPR), Disease-specific Exemptions 
from co-payment (DEX) and vital status.  
 
2.2 Algorithm to identify newly hospitalized HF cases 
Our primary definition of HF was based on diagnostic codes for heart failure (428.xx) and for 
hypertensive heart failure (402.01, 402.11, and 402.91), according to the International 
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), appearing as the 
primary diagnosis at the first hospitalization from HDA in the study period (referred to as index 
admission), as suggested by a recent study in the same setting [5]. Patients who had prior 
hospitalization with HF diagnosis (recorded as primary or secondary diagnoses in the previous 
five years) were excluded. 
 
2.3 Ascertainment of comorbidity  
Sixteen comorbid conditions were searched in the index admission for HF and in all hospital 
discharges in HDA that occurred within 12 months before the index date, following the Charlson  
algorithm [7]. We tried to maximize sensitivity in detecting comorbidities, by integrating the 
information from HDA with that recorded from DPR and DEX. 
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The mapping approach proposed by Huber et al [13] for detecting chronic conditions by using 
pharmacy data, was applied to ATC codes of medicaments dispensed at least twice within 12 
months prior to the index admission.   
All exemptions concerning any of the 16 conditions included in Charlson comorbidity index, still 
valid at the time of index admission or expired in the previous 12 months, were considered.  
Table 1 lists codes used to identify comorbidity in each data source. 
[ Table 1 about here] 
 
2.4 Statistical Analysis 
We estimated 1-year relative survival from HF through the transformation approach [14]. This 
method consists in a transformation of all the individual survival times to a different scale, by 
taking into account the general population mortality. The transformed outcome variable (y) 
measures how long, after the HF event, and relative to the respective population, a person has 
lived. Population life tables of Lombardy region were provided by the Italian National Institute of 
Statistics. 
Crude Kaplan-Meier survival probabilities, against y, were estimated both overall and stratified. 
Log-rank test was used to test survival differences. 
Furthermore, we built two comorbidity-adjusted Cox survival models on the transformed outcome, 
including gender, age and the 16 selected comorbid conditions contributing to Charlson index.  
One model uses the comorbidity information assessed in HDA database only, whereas the other 
uses the enhanced information from all sources. We calculated the c-statistic for each model. 
R software, version 3.3.0 and “relsurv” package were used. 
  
3. Results 
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A total of 51,061 incident HF subjects were identified in the years 2008-2010. The study cohort 
comprised predominantly women (53.2%) and elderly patients (median age of 80 years and 
interquartile range from 73 to 86 years). Thirty-three thousand and twenty-one subjects (64.7%) 
were entitled to a co-payment exemption. 
According to HDA only, at least one Charlson comorbid condition was detected for 50.9% of the 
study cohort. This figure raised up to 78.2% when integrating information from all sources. 
Integrating HDA with DEX and DPR data mainly affected prevalence of diabetes (from 19.2% to 
27.6%), chronic pulmonary disease (from 15.2% to 26.2%), cancer (from 6.4% to 11.1%), 
rheumatic disease (from 0.9% to 17.9%) and peptic ulcer (from 0.6% to 39.3%). Details about the 
prevalence of each comorbid condition by data source are shown in Table 1. 
After removing differences in structure for age, gender and calendar year, survival in the HF cohort 
is lower to that of the reference population (overall, 50% of HF patients died before their expected 
37th percentile) in any of the five comorbidity categories (Figure 1).  
[ Figure 1 about here] 
Furthermore, relative survival decreases with increasing number of comorbidities (log-rank test p-
value < 0.0001).  
Despite the discrepancies in the number of inferred comorbidities from HDA alone and in 
combination with DEX and DPR, the overall performance of the developed relative survival 
models was similar regardless of which data source was used. The difference among c-statistics 
was negligible, being 0.619 and 0.623 for the model with enhanced and original Charlson 
comorbidities, respectively.  
As shown in Figure 1, subjects with major non-cardiac comorbidities such as diabetes, chronic 
pulmonary disease exhibited a moderate increase in the hazard for HF death.  
 
4. Discussion 
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HF subjects typically suffer from a number of coexisting diseases that may influence the outcomes 
of care [2, 3, 15]. To the best of our knowledge, this is the first study (i) investigating a 
comprehensive search of comorbidities based on administrative data, (ii) assessing their impact on 
short-term survival, and (iii) trying to disentangle between mortality associated with HF from that 
due to all other causes through a relative survival approach. 
Our findings on the major non-cardiac comorbidities in HF patients, namely diabetes, chronic 
pulmonary disease and renal disease, are quite in line with those reported in the literature. Our 
estimate of diabetes prevalence (27.6%) is consistent with that reported from a population-based 
study [6] on English administrative data (26.6%) and from the Cardiovascular Health Study [16] 
(28.5%).  
Renal disease prevalence (14.2%) is slightly underestimated as compared to previous estimates [6, 
16, 17], ranging from 16.1% to 32.3%, probably because DPR was not exploited to infer this 
comorbidity [13]. Chronic pulmonary disease burden (26.2%) was higher than published estimates 
[6, 16, 17], varying between 19% and 20%, since we relied on a broader definition embracing 
chronic obstructive pulmonary disease and asthma as well.  
We observed that integrating HDA with other sources, mostly affected the detection of patients 
suffering from cancer, peptic ulcer and rheumatic disease. Nevertheless, these results should be 
interpreted with caution because the positive predictive value of the corresponding exemption code 
in identifying cancer is estimated to be 86% [18] and, as to peptic ulcer and rheumatic disease, we 
cannot rule out that the identified prescription patterns had low specificity in detecting the 
conditions of interest.  
The present study confirms that the high mortality observed among elderly with a first 
hospitalization for HF is higher than that of the reference population and is in part attributable to 
the impact of key baseline comorbidities. Consistently with previous findings [16], major non-
cardiac comorbidities exhibited a moderate increase in the hazard for HF death. Notably, the 
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overall performance of the developed relative survival models was similar regardless of which 
data source was used to ascertain comorbidity and was consistent with published findings [13]. 
Some study limitations must be acknowledged. The first stems from using administrative data 
sources and mostly concerns coding accuracy and lack of clinical information on important 
predictors of cardiovascular outcomes such as ejection fraction and New York Heart Association 
class. The lack of clinical and lifestyle predictors, most likely justifies the low discrimination 
ability of the developed relative survival model [19]. Secondly, with improvements in treatment 
and decreases in hospital resources, more patients with HF are being managed in the community 
[20]. As a result, patients identified in this study through hospital discharges will probably be more 
representative of medically complex HF population. 
Despite these limitations, this study demonstrates that the effort required to implement a 
comprehensive search method for comorbidities is worth the potential benefit when the aim is to 
assess the comorbidity burden. On the contrary, a search method, limited to HDA, data can 
reasonably be used to determine a profile of a HF patient’s comorbidity for mortality risk 
adjustment purposes.  
 
Contributions: IB designed the study and wrote the manuscript; IB and DA performed the 
statistical analysis; LS performed data extraction; all authors contributed to results interpretation 
and approved the final manuscript. 
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Figure legends 
Figure 1. Relative Survival analysis results. Panel A: Relative survival from HF by number of 
comorbidities. The estimated survival curve below/above the solid grey line indicates if the HF 
cohort does worse/better than the Lombardy reference population. Panel B: Forest plot of results 
from Cox model applied to transformed outcome y (which measures how long, after the HF event, 
and relative to the respective population, a person has lived) in the HF cohort (CPD: Chronic 
pulmonary disease, CVD: Cerebrovascular disease, MI: Myocardial infarction). 
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Table 1. Prevalence of Charlson comorbid conditions (excluding congestive heart failure) in the 
HF cohort by data source along with source-specific codes.  
HDA 
 
DPR 
 
DEX 
 
HDA+D
EX* 
HDA+DPR+
DEX* 
ICD-9-CM codes N(%) ATC codes 
N(
%) 
ICD-9-CM 
codes 
N(%) N(%) N(%) 
Diabetes without 
complications  
250, 250.0x–250.3x, 250.7x 
7,841 (15.4) 
Diabetes 
mellitus 
A10A, 
A10B, 
A10X 
11,0
97 
(21.
7) 
Diabetes  
mellitus  
250 
11,422 
(22.4) 
13,457 
(26.3) 
14,113 (27.6) 
Diabetes with complications 
250.4x–250.6x, 250.8x-250.9x 
1,959 (3.8) 
Chronic pulmonary disease 
490.xx-496, 500-505, 506.4 
7,765 (15.2) 
Respirator
y illness  
R03 
9,62
7 
(18.
8) 
Asthma 
 493 
211 (0.4) 
7,867 
(15.4) 
13,367 (26.2) 
Renal disease 
582.xx, 583.xx, 585.x, 586, 
588.xx 
6,849 (13.4) --- -- 
Chronic kidney 
disease 
585 
1143 (2.2) 
7,241 
(14.2) 
7,241 (14.2) 
Myocardial infarction 
410.xx, 412 
4,806 (9.4) --- --- --- --- 
4,806 
(9.4) 
4,806 (9.4) 
Any malignancy,  
including lymphoma and 
leukemia,  
except malignant neoplasm of 
skin 
140.x-171.x, 174.x.-195.x,  
200.x-208.x, 273.0, 
273.3,V10.46 
2,582 (5.1) Cancer 
L01 
 
606 
(1.2) 
 
Tumour 
048 
 
3,966 (7.7) 
5,431 
(10.6) 
5,743 (11.2) 
Metastatic solid tumor 
196.x-199.x 
692 (1.3) 
Peripheral vascular disease 
441.xx, 443.9, 785.4, V43.4;  
Procedures 38.13, 38.14, 38.16, 
38.18, 38.43, 38.44, 38.46, 
38.48, 38.33, 38.34, 38.36, 
38.38, 39.22-39.26, 39.28, 
39.29 
2,487 (4.9) --- --- 
Diseases of 
arteries, 
arterioles, and 
capillaries 
441.2, 441.4, 
441.7, 441.9, 
V43.4 
302 (0.6) 
2,694 
(5.3) 
2,727 (5.3) 
Cerebrovascular disease 
430-437.x, 438;  
Procedures 38.12, 38.42 
2,280 (4.5) --- --- 
Cerebrovascula
r disease 
433, 434, 437 
272 (0.5) 
2,485 
(4.9) 
2,485 (4.9) 
Mild liver disease 
571.2, 571.4x–571.6 
918 (1.8) --- --- 
Chronic liver 
disease  
and cirrhosis 
0 (0.0) 918 (1.8) 918 (1.8) 
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571.2, 571.5, 
571.6 
571.4 
Moderate or severe liver 
disease 
456.0-456.21, 572.2-572.8;  
Procedures 39.1, 42.91 
140 (0.3) --- --- --- --- 140 (0.3) 140 (0.3) 
Dementia 
290.xx 
560 (1.1) 
Dementia 
N06D 
352 
(0.7) 
Dementia 
290.0-290.2, 
290.4 
--- 560 (1.1) 830 (1.6) 
Rheumatic disease 
710.0, 710.1, 710.4, 714.0-
714.2, 714.81, 725 
437 (0.9) 
Rheumatol
ogic 
conditions 
M01, M02, 
L04AA, 
L04AB 
8,86
5 
(17.
4) 
Rheumatoid 
arthritis 
714.0-714.2 
--- 437 (0.9) 9,131 (17.9) 
Hemiplegia or paraplegia 
342.xx, 344.1 
350 (0.7) --- --- --- --- 350 (0.7) 350 (0.7) 
Peptic ulcer disease 
531.xx-534.xx 
298 (0.6) 
Acid 
related 
disorders 
A02 
24,3
22 
(47.
6) 
--- --- 298 (0.6) 20,071 (39.3) 
AIDS/HIV  
042.x–044.x 
18 (0.0) 
HIV 
J05AE, 
J05AG, 
J05AR 
0 
(0.0) 
HIV disease 
042 
0 (0.0) 18 (0.0) 18 (0.0) 
 
*: a comorbidity appearing in more than one source is counted once per patient. 
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